FDA cites GSK flu vaccine plant for quality violations

June 24, 2014 4:46 PM

8 0

FDA cites GSK flu vaccine plant for quality violations

WASHINGTON (Reuters) - A GlaxoSmithKline Plc plant in Canada that makes the flu vaccine Flulaval has been cited by the U.S. Food and Drug Administration for failing to meet quality control standards.

GSK said it is working to rectify the problems and does not expect a delay in distributing the vaccine for the 2014-2015 flu season. The company typically starts shipping the product at the end of July.

Read more

To category page

Loading...